Skip to main navigation
X-twitter-square Linkedin Instagram Facebook-square Youtube

NASDAQ: HELP | CBOE CA: HELP

  • Our Work
    • Clinical Trials
    • Development Pipeline
    • HLP003
    • HLP004
    • Intellectual Property
    • EMBARK
    • Scientific Publications
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials
      • Financials
      • SEC Filings
      • SEDAR Filings
    • Governance
      • Governance Documents
      • Shareholder Materials
      • Our Team
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contact
      • Whistleblower Resources
  • About Us
    • Our Team
    • Our Focus
    • Join Us
    • Contact Us
  • Our Work
    • Clinical Trials
    • Development Pipeline
    • HLP003
    • HLP004
    • Intellectual Property
    • EMBARK
    • Scientific Publications
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials
      • Financials
      • SEC Filings
      • SEDAR Filings
    • Governance
      • Governance Documents
      • Shareholder Materials
      • Our Team
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contact
      • Whistleblower Resources
  • About Us
    • Our Team
    • Our Focus
    • Join Us
    • Contact Us

News

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
November 16, 2026
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
November 16, 2026
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
November 15, 2026
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
November 3, 2026
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
October 27, 2026
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
October 21, 2026
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
October 15, 2026
Helus Pharma to Host Investor Presentation on October 21, 2026
October 8, 2026
Helus Pharma Announces Completion of Legal Name Change
October 1, 2026
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
September 22, 2026
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 39

Investor Email Alerts

X-twitter-square Linkedin Instagram Facebook-square Youtube

OUR WORK

  • Clinical Trials
  • Development Pipeline
  • HLP003
  • HLP004
  • Intellectual Property
  • EMBARK
  • Scientific Publications
  • Clinical Trials
  • Development Pipeline
  • HLP003
  • HLP004
  • Intellectual Property
  • EMBARK
  • Scientific Publications
INVESTORS
  • Overview
  • News
  • Events & Presentations
  • Financials
  • Governance
  • Whistleblower Resources
  • Overview
  • News
  • Events & Presentations
  • Financials
  • Governance
  • Whistleblower Resources

ABOUT US

  • Our Team
  • Our Focus
  • Join Us
  • Contact Us
  • Our Team
  • Our Focus
  • Join Us
  • Contact Us

TRADE

  • NASDAQ: HELP
  • CBOE CA: HELP
  • Helus Pharma© 2026. All rights reserved.
  • Privacy Policy
  • Employee Privacy Policy
  • Privacy Notice
Search Investors